Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent bcr-abl downregulation AC

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 151-163

  Shi, Xianping ^a   Chen, Xin ^a   Li, Xiaofen ^a   Lan, Xiaoying ^a   Zhao, Chong ^a   Liu, Shouting ^a   Huang, Hongbiao ^a   Liu, Ningning ^a   Liao, Siyan ^a   Song, Wenbin ^a   Zhou, Ping ^a   Wang, Shunqing ^a   Xu, Li ^b   Wang, Xuejun ^c   Dou, Q Ping ^d   Liu, Jinbao ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE; GAMBOGIC ACID; IMATINIB; PROTEASOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZAMIDES; CASPASES; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MONOCYTES; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRIMIDINES; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892176500     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1063     Document Type: Article

References (49)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53.
2. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia 2003;17:691-9.
3. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000;19:2523-31.
4. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 2000;275:39223-30.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
6. Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+ ) CD38(+) population to imatinib. Exp Hematol 2012;40:367-78.
7. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998;16:1383-90.
8. Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G, et al. Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia 2012;26:1555-63.
9. Jiang X, Stuible M, Chalandon Y, Li A, Chan WY, Eisterer W, et al. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 2003;102:2976-84.
10. Thienelt CD, Green K, Bowles DW. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today (Barc) 2012;48:601-13.
11. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem 2008;15:3036-51.
12. Druker BJ, Guilhot GF, O'Brien S, Larson N. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. Proc Am Soc Clin Oncol 2006;24:338S.
13. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. Newinsights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-23.
14. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005;1:183-7.
15. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009;15:1686-97.
16. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl + human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109:4006-15.
17. Zhang HZ, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 2004;12:309-17.
18. Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol 2005;11:3655-9.
19. Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao L, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci 2006;78:1238-45.
20. Chuah LO, Yeap SK, Ho WY, Beh BK, Alitheen NB. In vitro and in vivo toxicity of garcinia or hydroxycitric Acid: a review. Evid Based Complement Alternat Med 2012;2012:197920.
21. Marquez F, Babio N, Bullo M, Salas-Salvado J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr 2012;52:585-94.
22. Palempalli UD, Gandhi U, Kalantari P, Vunta H, Arner RJ, Narayan V, et al. Gambogic acid covalently modifies Ikappa B kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappa B in macrophages. Biochem J 2009;419:401-9.
23. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull 2004;27:998-1003.
24. Li X, Liu S, Huang H, Liu N, Zhao C, Liao S, et al. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep 2013;3:211-22.
25. Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010; 115:2241-50.
26. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 2009;69:6546-55.
27. Dou QP, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 1999;289:781-90.
28. Xu F, Shi X, Cheng C, Lu Z, Lai Y, Pan J. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Bioorg Med Chem 2010;18:1806-15.
29. Huang H, Zhang X, Li S, Liu N, Lian W, McDowell E, et al. Physiological levels of ATP negatively regulate proteasome function. Cell Res 2010; 20:1372-85.
30. Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther 2010;9:211-23.
31. Hisatomi T, Nakao S, Murakami Y, Noda K, Nakazawa T, Notomi S, et al. The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization. Am J Pathol 2012;181:53-61.
32. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
33. Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007;6:67.
34. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer 2008;122:2621-7.
35. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009;8:1924-33.
36. Beyazit Y, Kekilli M, Haznedaroglu IC. Second-generation BCR-ABL kinase inhibitors in CML. N Engl J Med 2010;363:1673.
37. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995;86:1148-58.
38. Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante- Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 2003;10:592-8.
39. Li R, Chen Y, Zeng LL, Shu WX, Zhao F, Wen L, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology 2009; 262:98-105.
40. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003;88:853-63.
41. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-5.
42. Di Bacco AM, Cotter TG. p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol 2002;117:588-97.
43. Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia 2010;24:115-24.
44. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117:3421-9.
45. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011;117:3409-20.
46. Ilaria RL Jr. Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:525-43.
47. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
48. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxideinduced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14:262-70.
49. Li JK, Yu L, Shen Y, Zhou LS, Wang YC, Zhang JH. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol 2008;14:2308-13.